Publications by authors named "Ralph Demasi"

Claim this Profile
A
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective.
Ann M Buchanan, Adrie Bekker, Hardik Chandasana, Ralph DeMasi, Zrinka Lulic

Int J Antimicrob Agents· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Responding to the Call to Action: Framework to Accelerate Clinical Data Generation for Antiretroviral Use in Pregnant Individuals with HIV.
Vani Vannappagari, Scott McCallister, Beth Romach, Mark Bush, Dinesh Stanislaus, Ralph DeMasi

Infect Dis Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups.
M Keith Rawlings, Emilio Letang, Romina Quercia, Richard Grove, Ralph DeMasi

Open Forum Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribavirin concentration determines treatment success of first-generation DAA-based chronic HCV therapy.
Clara Tmm de Kanter, Maria Buti, Ralph DeMasi, Sivi Ouwerkerk-Mahadevan, Anton Sm Dofferhoff

Antivir Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
Christophe Hézode, Piero L Almasio, Stefan Bourgeois, Peter Buggisch, Ashley Brown, Ralph DeMasi

Liver Int· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study.
Geert Robaeys, Stefan Christensen, Damien Lucidarme, Amber Arain, Philip Bruggmann, Ralph DeMasi

Infect Dis Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
Gianpiero D'Offizi, Calogero Cammà, Chiara Taibi, Michael Schlag, Karin Weber, Ralph DeMasi

New Microbiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study.
Imtiaz Alam, Kimberley Brown, Cynthia Donovan, Jamie Forlenza, Kris Lauwers, Ralph DeMasi

Open Forum Infect Dis· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.
Antonia Lepida, Massimo Colombo, Inmaculada Fernandez, Djamal Abdurakhmanov, Paulo Abrao Ferreira, Ralph DeMasi

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.
Andrea Gori, Manuela Doroana, Oksana Chernova, Jürgen K Rockstroh, Denes Banhegyi, Ralph DeMasi

J Infect· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial.
Anna Maria Geretti, Mathe Moeketsi, Ralph Demasi, Yvon van Delft, Perry Mohammed

AIDS Res Treat· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.
Steven L Flamm, Andrew J Muir, Michael W Fried, K Rajender Reddy, David R Nelson, Ralph DeMasi

J Clin Gastroenterol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When can HIV clinical trials detect treatment effects on drug resistance?
Andrew M Hill, Christiane Moecklinghoff, Ralph DeMasi

Int J STD AIDS· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
Thomas Berg, Pietro Andreone, Stanislas Pol, Stuart Roberts, Zobair Younossi, Ralph DeMasi

Liver Int· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
Massimo Colombo, Simone Strasser, Christophe Moreno, Paulo Abrao Ferreira, Petr Urbanek, Ralph DeMasi

J Hepatol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients.
Stefan Zeuzem, Ralph DeMasi, Alessandra Baldini, Bruce Coate, Donghan Luo

J Hepatol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RE: Non-specific effects of co-administration of live measles, yellow fever and pentavalent vaccines on mortality?
Daphné A Schmid, Patricia Ibarra de Palacios, Ralph DeMasi

Vaccine· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
Zobair Younossi, Francesco Negro, Lawrence Serfaty, Stanislas Pol, Moises Diago, Ralph DeMasi

Hepatology· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1.
Lawrence Serfaty, Xavier Forns, Tobias Goeser, Peter Ferenci, Frederik Nevens, Ralph DeMasi

Gut· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials.
David Anderson, Ralph DeMasi, Lori DeLaitsch, Tiffany Surles, Bruce Coate

Curr HIV Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.
Jan Fourie, Jason Flamm, Amalia Rodriguez-French, Don Kilby, Pere Domingo, Ralph DeMasi

HIV Clin Trials· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.
Mark Nelson, Pierre-Marie Girard, Ralph Demasi, Liddy Chen, Erik Smets

J Antimicrob Chemother· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does earlier HIV RNA suppression provide long-term benefits?
Graeme Moyle, Ralph Demasi, Andrew Hill

AIDS· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Friedewald equation underestimates low-denisty lipoprotein elevations for patients with high triglyceride levels in the ARTEMIS and TITAN trials.
Mark Nelson, Ralph DeMasi, Christiane Moecklinghoff, Andrew M Hill

J Acquir Immune Defic Syndr· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.
Sandra De Meyer, Andrew Hill, Gaston Picchio, Ralph DeMasi, Els De Paepe

J Acquir Immune Defic Syndr· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis